Partum Pharmaceutical is a research and development-focus biotechnology company that focus its robust discovery platform to create Cyclic peptides for transfection of therapeutic macromolecules.
We have established, maintained, and actively pursued intellectual property protection for our platform.
The global transfection reagent and equipment market size was valued at USD 706.26 million in 2016. It is expected to expand at a CAGR of 7.4%, and reach over USD 1.351 billion by 2025. The major factors driving the market growth include technological advancements in transfection, an increase in research and development expenditure, research activities by pharmaceutical and biotech companies, and increased demand for synthetic genes.